Publicaciones en las que colabora con José Luis Calleja Panero (14)

2024

  1. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease

    Journal of Hepatology, Vol. 81, Núm. 6, pp. 930-940

2023

  1. Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 3, pp. 128-132

  2. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 150-162

2022

  1. Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology

    Liver International, Vol. 42, Núm. 8, pp. 1783-1792

2021

  1. High liver stiffness values by transient elastography related to metabolic syndrome and harmful alcohol use in a large Spanish cohort

    United European Gastroenterology Journal, Vol. 9, Núm. 8, pp. 892-902

2020

  1. Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain

    Journal of Viral Hepatitis, Vol. 27, Núm. 4, pp. 360-370

  2. Update on epidemiology of hepatitis B in a low-endemic European country: There is still much to do

    Journal of Viral Hepatitis, Vol. 27, Núm. 11, pp. 1261-1265

2017

  1. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

  2. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort

    Journal of Hepatology, Vol. 66, Núm. 6, pp. 1138-1148

  3. Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System

    Medicina Clinica, Vol. 148, Núm. 6, pp. 277-282

  4. Real-World Effectiveness and Safety of Oral Combination Antiviral Therapy for Hepatitis C Virus Genotype 4 Infection

    Clinical Gastroenterology and Hepatology, Vol. 15, Núm. 6, pp. 945-949.e1

2015

  1. High efficacy and safety of triple therapy in hcv genotype 1 and moderate fibrosis: A multicenter study of clinical practice in Spain

    Annals of Hepatology, Vol. 14, Núm. 4, pp. 477-486

  2. Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153

  3. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program

    Journal of Viral Hepatitis, Vol. 22, Núm. 5, pp. 469-480